Survival rate and prognostic factors of conventional osteosarcoma in Northern Thailand: A series from Chiang Mai University Hospital

Pruksakorn, Dumnoensun; Phanphaisarn, Areerak; Arpornchayanon, Olarn; Uttamo, Nantawat; Leerapun, Taninnit; Settakorn, Jongkolnee

doi:10.1016/j.canep.2015.10.016

Cited by 22 publications

(27 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary tumor site was another independent osteosarcoma prognostic factor in our study, which was supported by most of the listed studies in Table 4 [ 2 , 15 , 17 , 18 , 28 ]. It is worth noting that Pruksakorn et al [ 18 ], Duchman et al [ 28 ], and Min et al [ 8 ] used the same categorization as ours in the analysis of tumor site which compared extremity tumors with axial tumors. Consistent with our data, Duchman et al [ 28 ] and Pruksakorn et al [ 18 ] reported that axial osteosarcomas have lower survival rate than the extremities.…”

Section: Discussionsupporting

confidence: 86%

“…Pakos et al [ 15 ] showed that the death risk of metastasis at diagnosis is nearly three folds than that of non-metastasis, while Janeway et al [ 17 ] reported that the presence of metastasis at diagnosis had a poorer survival in patients with high-grade osteosarcoma of any site enrolled on North American Cooperative Group. Similarly, the other four studies demonstrated that clinically detectable primary metastasis were significantly associated with inferior outcome [ 9 , 13 , 18 , 27 ].…”

Section: Discussionmentioning

confidence: 81%

See 1 more Smart Citation

The extremity localized classic osteosarcomas have better survival than the axial non-classics

Deng

Zhang

et al. 2018

World J Surg Onc

View full text Add to dashboard Cite

BackgroundOsteosarcoma is one of the most malignant primary bone cancers, while is rarely reported in China. Of note, very few data of prognosis has been documented in this region. Thus, we carried a retrospective study to identify prognostic factors and to analyze outcomes in patients of both classic and non-classic high-grade osteosarcomas. Classic osteosarcoma is defined as of high-grade histology, age below 40 years, with extremity localized primary tumor, and without detectable metastasis at primary diagnosis.MethodsA total of 98 patients (68 classic and 30 non-classic) aged from 4 to 64 years old were diagnosed as high-grade osteosarcoma from 2008 to 2015 in Nanfang Hospital, Guangzhou, China. Univariate and multivariate analyses were performed to identify the independent predictors for overall survival and event-free survival. Kaplan-Meier method was used for survival analysis.ResultsThe median overall survival was 117 vs. 21 months, and the median event-free survival was 31 vs. 6 months in classic and non-classic osteosarcoma, respectively. The most frequently found tumor site was around the knee. The classic osteosarcoma had better overall survival and event-free survival than the non-classics. Tumor site and primary metastasis were found to be associated with overall survival and event-free survival in the univariate analysis. In the multivariate Cox regression analysis, tumor site and primary metastasis were each verified as independent prognostic factors. However, no similar result was found in elevated serum alkaline phosphatase or lactate dehydrogenase. Amputation or limb salvage surgery had no significant effect on overall survival and event-free survival in the extremity osteosarcomas. Classic osteosarcomas with extremity tumor site and free of primary metastasis exhibited better overall survival and event-free survival, while the axial and metastatic non-classics exhibited the worse.ConclusionsThe extremity classic osteosarcomas have better survivals than the axial non-classic cases. Amputation and limb salvage surgery make no significant change in overall survival and event-free survival in the extremity osteosarcomas.Trial registrationNanfang2013071; Date of registration: 7 September 2013 (retrospectively registered).

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 81%

The extremity localized classic osteosarcomas have better survival than the axial non-classics

Deng

Zhang

et al. 2018

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…Survival of patients diagnosed with osteosarcoma has improved significantly over the past two decades with survival rate being reported to be from 55% to 80%. [1][2][3][4] However, the rates in many centres within the Asia-Pacific region are reported to be 27% to 48%, [4][5][6][7][8][9] which is not as high as the Caucasian population. Faisham et al 6 and Pruksakorn et al 7 attributed the low survival rate to patients' non-compliance to treatment regime.…”

Section: Introductionmentioning

confidence: 99%

Survival analysis of osteosarcoma patients: A 15-year experience

Yasin

Rashid

Singh

2020

J Orthop Surg (Hong Kong)

View full text Add to dashboard Cite

Introduction: Management of osteosarcoma has evolved considerably for the past two decades and there have been changes of practices especially pertaining to chemotherapy regime. This is a review of our cases in the past 15 years. Method: This is a retrospective survival analysis study of 128 patients treated at University Malaya Medical Centre (UMMC) from 1997 to 2011. Results: There were 80 (62.5%) male and 48 (37.5%) female patients with the median age being 15 (5–59). Majority had osteosarcoma of extremities (94.5%). More than 60% patients developed metastasis throughout the course of treatment with 39% presenting with lung metastasis. Osteoblastic osteosarcoma was the commonest subtype (65.6%). Of the 109 patients treated surgically, 84 patients (65.6%) underwent limb salvage surgery while the rest underwent amputation. Seventy-one per cent of patients completed treatment with local recurrence rate of 22.7%. The 5-year and 10-year survival rates were 56.31% (95% CI: 46.20, 65.24) and 22.33% (95% CI: 14.86, 30.76), respectively. The 5-year event-free survival was 52.94% (95% CI: 41.83, 62.87). In multivariate analysis, the independent prognostic factors were presence of metastasis and completion of treatment for both 5-year and 10-year overall survival. Good histological response was only significant for multivariate analysis at 5 years. Patients with metastasis had a hazard ratio of 20.4 at 5 years and 3.26 at 10 years. Conclusion: Overall survival rate for osteosarcoma patients at our centre was comparably higher than other centres in the region. Two independent risk factors for survival are metastatic status and completion of treatment. A standardized chemotherapy regime is essential for long-term survival.

show abstract

“…Osteosarcoma is one of the most common and aggressive malignant bone tumors, primarily occurring during adolescent growth and in the elderly [ 1 ]. Osteosarcoma incidence in adolescents is relatively consistent globally and ranges from 3–4.5 cases per million persons per year [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis

et al. 2017

View full text Add to dashboard Cite

To investigate correlations between excision repair cross-complementation group 1 (ERCC1) and 2 (ERCC2) polymorphisms and osteosarcoma prognosis, we conducted a meta-analysis of studies published through October 2016. Studies were identified in the PubMed, ScienceDirect, Springer, and Web of Science databases using preferred reporting items for systematic reviews and meta-analyses (PRISMA). Odds ratios (ORs) or hazard ratios (HRs) and their 95% confidence intervals (CIs) for overall survival (OS), tumor response (TR), and event-free survival (EFS) were estimated. Our meta-analysis included eleven studies in which four SNPs (ERCC1 rs11615 and rs3212986, ERCC2 rs13181 and rs1799793) reportedly associated with osteosarcoma prognosis were investigated. Each of these studies scored > 6 on the Newcastle-Ottawa Scale (NOS). We found that only one SNP, ERCC1 rs11615, correlated with improved OS and TR. The HR of T vs. C for OS was 1.455 (T/C, 95% CI = 1.151–1.839, P = 0.002, I2 = 37.80%). The OR of T vs. C for good TR was 0.554 (T/C, 95% CI = 0.437–0.702, P < 0.001, I2 = 0%). Few significant outcome was observed in subgroup analyses stratified based on study characteristics with adjustments for potential confounders. Our results suggest that ERCC1 rs11615 CC is associated with a better clinical outcome. This suggests rs11615 may be a useful genetic marker for predicting osteosarcoma prognosis.

show abstract

Survival rate and prognostic factors of conventional osteosarcoma in Northern Thailand: A series from Chiang Mai University Hospital

Cited by 22 publications

References 25 publications

The extremity localized classic osteosarcomas have better survival than the axial non-classics

The extremity localized classic osteosarcomas have better survival than the axial non-classics

Survival analysis of osteosarcoma patients: A 15-year experience

Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis

Contact Info

Product

Resources

About